While fundamental service revenue is declining, the influx of non-dilutive capital and regulatory milestones suggest de-risking of key programs. Traders should monitor the April 16, 2026 program update for AAV2-hAQP1 commercial data and watch for initiation of the AAV-GAD Phase 3 trial as near-term catalysts. The stock may react positively to clinical progress despite weak core revenue trends.
Price Chart
Executive Summary
MeiraGTx reported financial results for 2025, highlighted by a significant decline in service revenue and a net loss reduction to $114.2M, alongside transformative strategic collaborations with Lilly and Hologen that brought in $75M and $200M, respectively. The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 in xerostomia and RMAT for AAV-GAD in Parkinson’s, marking key clinical advancements. Despite declining core revenues, non-dilutive funding and expanded pipelines bolster near-term runway into 2027.
Key Financial Metrics
Key Facts
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia
- Strategic collaboration with Hologen yielded $200M upfront and up to $230M in committed funding for AAV-GAD development
- Lilly collaboration brought $75M upfront and potential for over $400M in milestones for AAV-AIPL1 and ocular assets
- Service revenue dropped 80.7% YoY to $6.4M due to completion of PPQ services under J&J agreement
- License revenue surged to $75.0M from $0 in 2024 due to Lilly upfront payment
- Net loss narrowed to $114.2M in 2025 from $147.8M in 2024
- Cash and equivalents declined to $65.9M as of Dec 31, 2025, from $105.7M in 2024
- Company expects sufficient capital into second half of 2027, including $95M remaining from Hologen deal
- Phase 3 study of AAV-GAD in Parkinson’s expected to initiate in coming months with Hologen AI support
- Ribo-leptin IND planned for 2026; riboswitch platform advancing in metabolic and neuropathic pain
Financial Impact
Revenue mix shifted dramatically: $75M in non-recurring license revenue offsetting $26.9M drop in service revenue. Strategic deals added $275M in non-dilutive capital. R&D increased $10.1M to $129.6M as clinical programs advanced.
Risk Factors
- Heavy reliance on milestone-dependent partnerships (Lilly, J&J) for future funding
- Service revenue collapse indicates shrinking core operations as J&J manufacturing work ends
- No near-term product revenue; all value hinges on clinical and regulatory success
- High cash burn: $65.9M cash with $75M debt due by mid-2027 creates future financing risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 144 | $10.82 | awaiting T+60 | — | $9.40 (−13.12%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.40 (−13.84%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.40 (−20.00%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.40 (−37.21%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.40 (−35.88%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.40 (−1.88%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers